Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: dutton: we are raising our price target to $0.90 per share

I think that PTSC will find a way to release the numbers indirectly.

For example, I can see Turley doing a post settlement interview in which he discusses the resources the company has at that point to use toward an M&A strategy and indicating that "with the licenses signed since the end of the last quarter, we now have over X in cash to pursue our acquisition strategy".  Doesn't disclose the actual amounts, but gives the market enough info to back into an order of magnitude on what the setttlements might have been, but subtracting the last quarter's cash position from the amount given, and by ballparking what the non-settlement licenses might have been worth would give one an idea of what the settlement was.  I think a good CEO will work his comments in a way to provide info that the market needs to analyze his company properly.

Share
New Message
Please login to post a reply